RxDoctor Payments Data

Lori-Anne Schulte-Laird

Psychiatric/Mental Health · Cleveland, OHNPI 1558696013

Payments from drug & device makers

$866in general payments, 2019–2025

Across 31 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$337
  • Johnson & Johnson$150
  • Lundbeck LLC$82
  • Otsuka America Pharmaceutical, Inc.$76
  • Axsome Therapeutics, Inc.$71
  • Sunovion Pharmaceuticals Inc.$54
  • plus $96 from 3 others

What the payments were for

  • Food & beverage$866100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$866 in reported general payments places this provider in the 55th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$15,480
Medicare patients
50
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole74$149,752
CaplytaLumateperone Tosylate47$99,816
VraylarCariprazine Hcl30$45,228
AuvelityDextromethorphan Hbr/Bupropion32$34,325
TrintellixVortioxetine Hydrobromide11$24,579
Aripiprazole69$11,889
Lurasidone Hcl57$11,323
Risperdal ConstaRisperidone Microspheres19$10,327
Quetiapine Fumarate ErQuetiapine Fumarate97$6,024
Ramelteon19$4,578
Quetiapine Fumarate117$3,772
Duloxetine Hcl90$3,364
Olanzapine119$3,324
Hydroxyzine Hcl81$3,109
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine61$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$76$149,75274 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$99,81647 claims
AbbVieVraylar$337$45,22830 claims
Axsome Therapeutics, Inc.Auvelity$71$34,32532 claims
Johnson & JohnsonRisperdal Consta$150$10,32719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →